APA (7th ed.) Citation

A, S., D, Z., R, P., DH, K., M, P., AM, S., . . . W, M. (2026). Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. Molecular cancer therapeutics, 25(7), 1157. https://doi.org/10.1158/1535-7163.MCT-25-0082

Chicago Style (17th ed.) Citation

A, Savoca, et al. "Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors." Molecular Cancer Therapeutics 25, no. 7 (2026): 1157. https://doi.org/10.1158/1535-7163.MCT-25-0082.

MLA (9th ed.) Citation

A, Savoca, et al. "Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors." Molecular Cancer Therapeutics, vol. 25, no. 7, 2026, p. 1157, https://doi.org/10.1158/1535-7163.MCT-25-0082.